H. Amy Xia - Concepedia

Author

H. Amy Xia

Amgen (United States)ORCID

Also Known As

H A Xia, H Amy Xia, H. Amy Xia, H. Xia, Hong Amy Xia, Hong Xia, Xia Hong, Xia, H. Amy, Xia, Hong Amy

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Amgen (United States)Eli Lilly (United States)University of Minnesota Merck & Co., Inc., Rahway, NJ, USA (United States)Novartis (Switzerland)

About

H. Amy Xia is an author at Amgen (United States) specializing in medicine, biostatistics, and safety science.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	452
2	Biostatistics	6	6	316
3	Engineering	4	4	113
4	Public Health	4	4	274
5	Education	1	1	87

H. Amy Xia

Publications

996

Citations

H-Index

Page 1

	Year	Citations
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis Angela Moore, Kenneth B. Gordon, Sewon Kang, Journal of the American Academy of Dermatology Open-label TrialContinuous VersusMedicineEtanercept TherapyClinical Trials	2006	156
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team Brenda Crowe, H. Amy Xia, Jesse A. Berlin, Clinical Trials	2009	113
Safety Monitoring in Clinical Trials Bin Yao, Li Zhu, Qi Jiang, Pharmaceutics Safety ScienceSafety MonitoringBayesian FrameworkClinical TrialsDrug Monitoring	2013	103
Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation Margaret Gamalo, Jasmina Savić, Cynthia Basu, Pharmaceutical Statistics Bayesian StatisticEducationBayesian Statistical MethodsBayesian InferencePediatric Epidemiology	2017	87
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices Alice B. Gottlieb, Philip J. Mease, J. Mark Jackson, Journal of Dermatological Treatment	2006	85
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry Arthur L. Weaver, Richard L. Lautzenheiser, Michael Schiff, Current Medical Research and Opinion	2005	65
Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment Joel M. Gelfand, Alexa B. Kimball, Eliot N. Mostow, Value in Health Disease ManagementPatient-reported OutcomesPsoriatic ArthritisOutcomes ResearchClinical Dermatology	2007	61
Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials H. Amy Xia, Haijun Ma, Bradley P. Carlin Journal of Biopharmaceutical Statistics Bayesian StatisticEngineeringSafety ScienceSafety SignalsBayesian Inference	2011	59
CD8 T cell-derived perforin aggravates secondary spinal cord injury through destroying the blood-spinal cord barrier Zhaoxiang Liu, Hua Zhang, H. Amy Xia, Biochemical and Biophysical Research Communications InflammationNeuroregenerationSpinal Cord InjuryPeripheral Nerve InjuryBlood-spinal Cord Barrier	2019	53
Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Joseph G. Ibrahim, Ming‐Hui Chen, H. Amy Xia, Biometrics	2011	50

Page 1